Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

"The pieces are coming together." Recursion, along with dozens of other young biotechs, is hoping that deep learning and other AI and big data techniques will lead to new kinds of therapies.

Two data readouts are expected from Recursion Pharmaceuticals in 2nd half of 2024. Click here to learn more about them.

The incorporation of real-world data from HealthVerity Marketplace will further strengthen Recursion's ability to predict patient responses, refine study designs, and ensure clinical trial sites ...

Explore RXRX's upcoming H2'25 trial updates for REC-4881 in familial adenomatous polyposis and REC-617.

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...

Recursion plucks J&J chief data science officer. Canaan adds ex-Pfizer R&D leader as venture partner. Obesity-focused Metsera unveils leadership team.

Recursion on Tuesday held a webinar to discuss results from the Phase 1/2 study of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The results were presented at an AACR Special ...

We recently published a list of 12 Cheap AI Stocks to Buy in 2025. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other cheap AI ...

Recursion Pharmaceuticals Inc RXRX shares are trading lower. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM).